Cited by 801Protein Kinase Regulation and GTPase SignalingProtein Tyrosine PhosphatasesMelanoma and MAPK Pathways

The DOI matches its Crossref record; 86 of the 87 references it cites were found in a registry or an index.

Dragging Ras Back in the Ring

Open access

Stephen, Andrew G., Esposito, Dominic, Bagni, Rachel K., McCormick, Frank·2014·Cancer Cell

DOI 10.1016/j.ccr.2014.02.017

Open this paper in CoChat — free account Open PDF

Abstract

Ras proteins play a major role in human cancers but have not yielded to therapeutic attack. Ras-driven cancers are among the most difficult to treat and often excluded from therapies. The Ras proteins have been termed "undruggable," based on failures from an era in which understanding of signaling transduction, feedback loops, redundancy, tumor heterogeneity, and Ras' oncogenic role was poor. Structures of Ras oncoproteins bound to their effectors or regulators are unsolved, and it is unknown precisely how Ras proteins activate their downstream targets. These knowledge gaps have impaired development of therapeutic strategies. A better understanding of Ras biology and biochemistry, coupled with new ways of targeting undruggable proteins, is likely to lead to new ways of defeating Ras-driven cancers.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2014.02.017

Cites

86 of 86 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
ras GENES
Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D. B., Tolcher, A. W., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,541
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
GEFs and GAPs: Critical Elements in the Control of Small G Proteins
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903
Ras oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467
A Cytoplasmic Protein Stimulates Normal N- ras p21 GTPase, But Does Not Affect Oncogenic Mutants
Trahey, M., & McCormick, F. (1987) · Science · doi:10.1126/science.2821624 · Cited by 1,211
Self-citation
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Abou‐Alfa, G. K., Schwartz, L. H., Ricci, S., Amadori, D., Santoro, A., Figer, A., Grève, J. D., Douillard, J., Lathia, C. D., Schwartz, B. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.3441 · Cited by 1,195

Flagged first, then by citations

Show all 87 references

1 of the 87 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 801

Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition
Tsai, Y. S., Woodcock, M. G., Azam, S. H., Thorne, L. B., Kanchi, K. L., Parker, J. S., Vincent, B. G., & Pecot, C. V. (2022) · Journal of Clinical Investigation · doi:10.1172/jci155523 · Cited by 103
Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange
Guillard, S., Kolasinska-Zwierz, P., Debreczeni, J. E., Breed, J., Zhang, J., Béry, N., Marwood, R., Tart, J., Overman, R., Stocki, P., et al. (2017) · Nature Communications · doi:10.1038/ncomms16111 · Cited by 97
A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer
Bangi, E., Ang, C., Smibert, P., Uzilov, A. V., Teague, A., Antipin, Y., Chen, R., Hecht, C., Gruszczynski, N., Yon, W. J., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav6528 · Cited by 102
Aberrant phase separation and cancer
Taniue, K., & Akimitsu, N. (2021) · FEBS Journal · doi:10.1111/febs.15765 · Cited by 101
Mutant KRAS promotes malignant pleural effusion formation
Agalioti, T., Giannou, A. D., Krontira, A. C., Kanellakis, N. I., Kati, D., Vreka, M., Pepe, M. A. A., Σπέλλα, Μ., Lilis, I., Zazara, D. E., et al. (2017) · Nature Communications · doi:10.1038/ncomms15205 · Cited by 103
Protein S-palmitoylation and cancer
Yeste‐Velasco, M., Linder, M. E., & Lu, Y. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.06.004 · Cited by 100
Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance
Dietrich, P., Koch, A., FRITZ, V. K., Hartmann, A., Bosserhoff, A., & Hellerbrand, C. (2017) · Gut · doi:10.1136/gutjnl-2017-315402 · Cited by 99
SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy
Wang, Z., Hausmann, S., Lyu, R., Li, T., Lofgren, S., Flores, N. M., Fuentes, M. E., Caporicci, M., Yang, Z., Meiners, M. J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.04.014 · Cited by 98
KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe
Bery, N., Legg, S., Debreczeni, J., Breed, J., Embrey, K., Stubbs, C., Kolasinska-Zwierz, P., Barrett, N., Marwood, R., Watson, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10419-2 · Cited by 97
Multiplexed in vivo homology-directed repair and tumor barcoding enables parallel quantification of Kras variant oncogenicity
Winters, I. P., Chiou, S., Paulk, N. K., McFarland, C. D., Lalgudi, P. V., Ma, R. K., Lisowski, L., Connolly, A. J., Petrov, D. A., Kay, M. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01519-y · Cited by 94
Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets
Enkner, F., Pichlhöfer, B., Zaharie, A., Krunic, M., Holper, T. M., Janik, S., Moser, B., Schlangen, K., Neudert, B., Walter, K., et al. (2016) · Pathology & Oncology Research · doi:10.1007/s12253-016-0144-8 · Cited by 97
Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis
Yin, C., Zhu, B., Zhang, T., Liu, T., Chen, S., Liu, Y., Li, X., Miao, X., Li, S., Mi, X., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.002 · Cited by 94
Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling
Dhawan, N. S., Scopton, A. P., & Dar, A. C. (2016) · Nature · doi:10.1038/nature19327 · Cited by 94
Membrane-associated Ras dimers are isoform-specific: K-Ras dimers differ from H-Ras dimers
Jang, H., Muratcioğlu, S., Gürsoy, A., Keskin, Ö., & Nussinov, R. (2016) · Biochemical Journal · doi:10.1042/bcj20160031 · Cited by 91
RNA G-Quadruplexes in Kirsten Ras ( KRAS ) Oncogene as Targets for Small Molecules Inhibiting Translation
Miglietta, G., Cogoi, S., Marinello, J., Capranico, G., Tikhomirov, A. S., Shchekotikhin, A. E., & Xodo, L. E. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00622 · Cited by 94
Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability
Adhikari, H., & Counter, C. M. (2018) · Nature Communications · doi:10.1038/s41467-018-05692-6 · Cited by 90
Oncogenic G12D mutation alters local conformations and dynamics of K-Ras
Vatansever, S., Erman, B., & Gumus, Z. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-48029-z · Cited by 89
Machine learning–driven multiscale modeling reveals lipid-dependent dynamics of RAS signaling proteins
Ingólfsson, H. I., Neale, C., Carpenter, T. S., Shrestha, R., López, C. A., Tran, T. H., Oppelstrup, T., Bhatia, H., Stanton, L. G., Zhang, X., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2113297119 · Cited by 96
Self-citation
RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer
Kang, R., Hou, W., Zhang, Q., Chen, R., Lee, Y. J., Bartlett, D. L., Lotze, M. T., Tang, D., & Zeh, H. J. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.445 · Cited by 93
Inhibition of K-RAS4B by a Unique Mechanism of Action: Stabilizing Membrane-Dependent Occlusion of the Effector-Binding Site
Fang, Z., Marshall, C. B., Nishikawa, T., Gossert, A. D., Jansen, J. M., Jahnke, W., & Ikura, M. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.07.009 · Cited by 86
Ras drives malignancy through stem cell crosstalk with the microenvironment
Yuan, S., Stewart, K. S., Yang, Y., Abdusselamoglu, M. D., Parigi, S. M., Feinberg, T. Y., Tumaneng, K., Yang, H., Levorse, J. M., Polak, L., et al. (2022) · Nature · doi:10.1038/s41586-022-05475-6 · Cited by 91
Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins
Martinko, A. J., Truillet, C., Julien, O., Diaz, J. E., Horlbeck, M. A., Whiteley, G., Blonder, J., Weissman, J. S., Bandyopadhyay, S., Evans, M. J., et al. (2018) · eLife · doi:10.7554/elife.31098 · Cited by 91
Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers
Aguirre, A. J., & Hahn, W. C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031518 · Cited by 90
Discovery of High-Affinity Noncovalent Allosteric KRAS Inhibitors That Disrupt Effector Binding
McCarthy, M. J., Pagba, C. V., Prakash, P., Naji, A. K., van der Hoeven, D., Liang, H., Gupta, A. K., Zhou, Y., Cho, K.-J., Hancock, J. F., et al. (2019) · ACS Omega · doi:10.1021/acsomega.8b03308 · Cited by 90
Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers
Sulahian, R., Kwon, J. J., Walsh, K. H., Pailler, E., Bosse, T. L., Thaker, M., Almanza, D., Dempster, J. M., Pan, J., Piccioni, F., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.090 · Cited by 90
A PDE6δ‐KRas Inhibitor Chemotype with up to Seven H‐Bonds and Picomolar Affinity that Prevents Efficient Inhibitor Release by Arl2
Martín‐Gago, P., Fansa, E. K., Klein, C. H., Murarka, S., Janning, P., Schürmann, M., Metz, M., Ismail, S., Schultz‐Fademrecht, C., Baumann, M., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201610957 · Cited by 90
Orthogonal ring-closing alkyne and olefin metathesis for the synthesis of small GTPase-targeting bicyclic peptides
Cromm, P. M., Schaubach, S., Spiegel, J., Fürstner, A., Grossmann, T. N., & Waldmann, H. (2016) · Nature Communications · doi:10.1038/ncomms11300 · Cited by 93
Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies
Park, K., Veena, M. S., & Shin, D. S. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.830208 · Cited by 91
Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 update
Roskoski, R. J. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107723 · Cited by 104
Direct inhibition of RAS: Quest for the Holy Grail?
Spencer-Smith, R., & O’Bryan, J. P. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.005 · Cited by 90
Macropinocytosis Exploitation by Cancers and Cancer Therapeutics
Ha, K. D., Bidlingmaier, S. M., & Liu, B. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00381 · Cited by 88
Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition
Tsai, Y., Woodcock, M. G., Azam, S. H., Thorne, L. B., Kanchi, K., Parker, J. S., Vincent, B. G., & Pecot, C. V. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 87
Assessment of mutation probabilities of KRAS G12 missense mutants and their long-timescale dynamics by atomistic molecular simulations and Markov state modeling
Pantsar, T., Rissanen, S., Dauch, D., Laitinen, T., Vattulainen, I., & Poso, A. (2018) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006458 · Cited by 85
Inflammation as a driver and vulnerability of KRAS mediated oncogenesis
Kitajima, S., Thummalapalli, R., & Barbie, D. A. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.06.009 · Cited by 83
Clinical and Molecular Characteristics of NF1 -Mutant Lung Cancer
Redig, A. J., Capelletti, M., Dahlberg, S. E., Sholl, L. M., Mach, S. L., Fontes, C., Shi, Y., Chalasani, P., & Janne, P. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2377 · Cited by 84
Lipid Metabolism Regulates Oxidative Stress and Ferroptosis in RAS-Driven Cancers: A Perspective on Cancer Progression and Therapy
Bartolacci, C., Andreani, C., Elgammal, Y., & Scaglioni, P. P. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.706650 · Cited by 86
MAPK kinase signalling dynamics regulate cell fate decisions and drug resistance
Rauch, N., Rukhlenko, O. S., Kölch, W., & Kholodenko, B. Ν. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.07.019 · Cited by 86
Molecular recognition of RAS/RAF complex at the membrane: Role of RAF cysteine-rich domain
Travers, T. S., López, C. A., Van, Q. N., Neale, C., Tonelli, M., Stephen, A. G., & Gnanakaran, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-26832-4 · Cited by 82
Self-citation
High-affinity interaction of the K-Ras4B hypervariable region with the RAS active site
Chavan, T. S., Jang, H., Khavrutskii, L., Abraham, S. J., Banerjee, A., Freed, B. C., Johannessen, L., Tarasov, S. G., Gaponenko, V., Nussinov, R., et al. (2015) · Biophysical Journal · doi:10.1016/j.bpj.2015.09.034 · Cited by 79
Activation of RAS family members confers resistance to ROS1 targeting drugs
Cargnelutti, M., Corso, S., Pergolizzi, M., Mévellec, L., Aisner, D. L., Dziadziuszko, R., Varella‐Garcia, M., Comoglio, P. M., Doebele, R. C., Vialard, J. E., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.3311 · Cited by 80
Farnesylated and methylated KRAS4b: high yield production of protein suitable for biophysical studies of prenylated protein-lipid interactions
Gillette, W., Esposito, D., Blanco, M. A., Alexander, P., Bindu, L. K., Bittner, C., Chertov, O., Frank, P. H., Grose, C., Jones, J. E., et al. (2015) · Scientific Reports · doi:10.1038/srep15916 · Cited by 80
Self-citation
ADAM17: An Emerging Therapeutic Target for Lung Cancer
Saad, M. I., Rose‐John, S., & Jenkins, B. J. (2019) · Cancers · doi:10.3390/cancers11091218 · Cited by 81
Nanodiscs: A Controlled Bilayer Surface for the Study of Membrane Proteins
McLean, M. A., Gregory, M. C., & Sligar, S. G. (2018) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-070816-033620 · Cited by 78
Two Distinct Structures of Membrane‐Associated Homodimers of GTP‐ and GDP‐Bound KRAS4B Revealed by Paramagnetic Relaxation Enhancement
Lee, K., Fang, Z., Enomoto, M., Gasmi-Seabrook, G. M. C., Zheng, L., Koide, S., Ikura, M., & Marshall, C. B. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202001758 · Cited by 78
DARPA's Big Mechanism program
Cohen, P. R. (2015) · Physical Biology · doi:10.1088/1478-3975/12/4/045008 · Cited by 82
Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors
Yen, I., Shanahan, F., Merchant, M. A., Orr, C., Hunsaker, T., Durk, M. R., La, H., Zhang, X., Martin, S. E., Lin, E., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.09.002 · Cited by 77
Rare codons capacitate Kras-driven de novo tumorigenesis
Pershing, N. L. K., Lampson, B. L., Belsky, J. A., Kaltenbrun, E., MacAlpine, D. M., & Counter, C. M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77627 · Cited by 77
Predictive value of oncogenic driver subtype, programmed death‐1 ligand (PD‐L1) score, and smoking status on the efficacy of PD‐1/PD‐L1 inhibitors in patients with oncogene‐driven non–small cell lung cancer
Ng, T. L., Liu, Y., Dimou, A., Patil, T., Aisner, D. L., Dong, Z., Jiang, T., Su, C., Wu, C., Ren, S., et al. (2018) · Cancer · doi:10.1002/cncr.31871 · Cited by 78
Highly Potent, Selective, Biostable, and Cell-Permeable Cyclic d -Peptide for Dual-Targeting Therapy of Lung Cancer
Zhou, Y., Zou, Y., Yang, M., Mei, S., Liu, X., Han, H., Zhang, C.-D., & Niu, M. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c12075 · Cited by 77
Drosophila melanogaster: A platform for anticancer drug discovery and personalized therapies
Munnik, C., Xaba, M. P., Malindisa, S. T., Russell, B. L., & Sooklal, S. A. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.949241 · Cited by 80
Direct Modulation of Small GTPase Activity and Function
Cromm, P. M., Spiegel, J., Grossmann, T. N., & Waldmann, H. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201504357 · Cited by 80
Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9
Yu, B., Swatkoski, S., Holly, A. J., Lee, L. C., Giroux, V., Lee, C.-S., Hsu, D. J., Smith, J. L., Yuen, G., Yue, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415569112 · Cited by 76
Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS
Kitajima, S., Asahina, H., Chen, T., Guo, S., Quiceno, L. G., Cavanaugh, J. D., Merlino, A. A., Tange, S., Terai, H., Kim, J. W., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.009 · Cited by 75
Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects
Marcus, K., & Mattos, C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2148 · Cited by 75
miR-137 Modulates a Tumor Suppressor Network-Inducing Senescence in Pancreatic Cancer Cells
Neault, M., Mallette, F. A., & Richard, S. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.068 · Cited by 78
Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1
Mao, Y., XI, L., Li, Q., Cai, Z., Lai, Y., Zhang, X., & Yu, C. (2016) · Oncology Reports · doi:10.3892/or.2016.4820 · Cited by 75
α5β1-Integrin promotes tension-dependent mammary epithelial cell invasion by engaging the fibronectin synergy site
Miroshnikova, Y. A., Rozenberg, G. I., Cassereau, L., Pickup, M. W., Mouw, J. K., Ou, G., Templeman, K. L., Hannachi, E.-I., Gooch, K. J., Sieminski, A. L., et al. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-02-0126 · Cited by 74
Progress in the Treatment of Metastatic Pancreatic Cancer and the Search for Next Opportunities
Ko, A. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7625 · Cited by 74
PI3K: A Crucial Piece in the RAS Signaling PuzzlePreprint
Krygowska, A. A., & Castellano, E. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031450 · Cited by 79
Inhibitors of Ras–SOS Interactions
Lu, S., Jang, H., Zhang, J., & Nussinov, R. (2016) · ChemMedChem · doi:10.1002/cmdc.201500481 · Cited by 72
The cornerstone K-RAS mutation in pancreatic adenocarcinoma: From cell signaling network, target genes, biological processes to therapeutic targeting
Jonckheere, N., Vasseur, R., & SEUNINGEN, I. V. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.002 · Cited by 73
Palmitoylacyltransferase Zdhhc9 inactivation mitigates leukemogenic potential of oncogenic Nras
Liu, P., Jiao, B., Zhang, R., Zhao, H., Zhang, C., Wu, M. H., Li, D., Zhao, X., Qiu, Q., Li, J., et al. (2015) · Leukemia · doi:10.1038/leu.2015.293 · Cited by 72
K-Ras4B Remains Monomeric on Membranes over a Wide Range of Surface Densities and Lipid Compositions
Chung, J. K., Lee, Y. K., Denson, J.-P., Gillette, W., Alvarez, S. A., Stephen, A. G., & Groves, J. T. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2017.10.042 · Cited by 72
Self-citation
Covalent Guanosine Mimetic Inhibitors of G12C KRAS
Xiong, Y., Lu, J., Hunter, J., Li, L., Scott, D., Choi, H. G., Lim, S. M., Manandhar, A., Gondi, S., Sim, T., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00373 · Cited by 66
Protein–Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway
García-Gómez, R., Bustelo, X. R., & Crespo, P. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.07.002 · Cited by 72
Similarity in gene-regulatory networks suggests that cancer cells share characteristics of embryonic neural cells
Zhang, Z., Lei, A., Xu, L., Chen, L., Chen, Y., Zhang, X., Gao, Y., Yang, X., Zhang, M., & Cao, Y. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.785865 · Cited by 73
Identification of Key Genes Related to Lung Squamous Cell Carcinoma Using Bioinformatics Analysis
Gao, M., Kong, W., Huang, Z., & Xie, Z. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082994 · Cited by 73
Binding hotspots on K-ras: Consensus ligand binding sites and other reactive regions from probe-based molecular dynamics analysis
Prakash, P., Hancock, J. F., & Gorfe, A. A. (2015) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24786 · Cited by 69
Intercellular Transfer of Oncogenic KRAS via Tunneling Nanotubes Introduces Intracellular Mutational Heterogeneity in Colon Cancer Cells
Desir, S., Wong, P., Turbyville, T. J., Chen, D., Shetty, M., Clark, C., Zhai, E., Romin, Y., Manova-Todorova, K. O., Starr, T. K., et al. (2019) · Cancers · doi:10.3390/cancers11070892 · Cited by 69
Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling
Rukhlenko, O. S., Khorsand, F., Krstić, A., Rožanc, J., Alexopoulos, L. G., Rauch, N., Erickson, K. E., Hlavacek, W. S., Posner, R. G., Gómez‐Coca, S., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.06.002 · Cited by 68
Aurora kinase targeting in lung cancer reduces KRAS-induced transformation
dos Santos, E. O., Carneiro-Lobo, T. C., Aoki, M. N., Levantini, E., & Bassères, D. S. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0494-6 · Cited by 64
An engineered protein antagonist of K-Ras/B-Raf interaction
Kauke, M. J., Traxlmayr, M. W., Parker, J. A., Kiefer, J. D., Knihtila, R., McGee, J., Verdine, G., Mattos, C., & Wittrup, K. D. (2017) · Scientific Reports · doi:10.1038/s41598-017-05889-7 · Cited by 64
A systems mechanism for KRAS mutant allele–specific responses to targeted therapy
McFall, T., Diedrich, J. K., Mengistu, M., Littlechild, S. L., Paskvan, K. V., Sisk-Hackworth, L., Moresco, J. J., Shaw, A. S., & Stites, E. C. (2019) · Science Signaling · doi:10.1126/scisignal.aaw8288 · Cited by 65
Developments in targeted therapy in melanoma
Amann, V. C., Ramelyte, E., Thurneysen, S., Pitocco, R., Jaberg-Bentele, N. F., Goldinger, S. M., Dummer, R., & Mangana, J. (2016) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2016.10.014 · Cited by 71
Progress in targeting RAS with small molecule drugs
McCormick, F. P. (2019) · Biochemical Journal · doi:10.1042/bcj20170441 · Cited by 64
Self-citation
The human AP-endonuclease 1 (APE1) is a DNA G-quadruplex structure binding protein and regulatesKRASexpression in pancreatic ductal adenocarcinoma cells
Pramanik, S., Chen, Y., Song, H., Khutsishvili, I., Marky, L. A., Ray, S., Natarajan, A., Singh, P. K., & Bhakat, K. K. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac172 · Cited by 60
Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models
Hu, C., Dadon, T., Chenna, V., Yabuuchi, S., Bannerji, R., Booher, R., Strack, P. R., Azad, N. S., Nelkin, B. D., & Maitra, A. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0028 · Cited by 65
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Xu, K., Park, D., Magis, A. T., Zhang, J., Zhou, W., Sica, G., Ramalingam, S. S., Curran, W. J., & Deng, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1012-4 · Cited by 71
Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant–driven tumor growth
Shin, S., Kim, J., Park, S.-W., Jun, S.-Y., Kweon, H.-J., Choi, D.-K., Lee, D., Cho, Y. B., & Kim, Y. (2020) · Science Advances · doi:10.1126/sciadv.aay2174 · Cited by 63
Selective Endothelial Hyperactivation of Oncogenic KRAS Induces Brain Arteriovenous Malformations in Mice
Park, E. S., Kim, S., Huang, S., Yoo, J. Y., Körbelin, J., Lee, T. J., Kaur, B., Dash, P. K., Chen, P. R., & Kim, E. (2021) · Annals of Neurology · doi:10.1002/ana.26059 · Cited by 63
One-way membrane trafficking of SOS in receptor-triggered Ras activation
Christensen, S. M., Tu, H., Jun, J. E., Alvarez, S. A., Triplet, M. G., Iwig, J. S., Yadav, K. K., Bar‐Sagi, D., Roose, J. P., & Groves, J. T. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3275 · Cited by 62
Thyroid C-Cell Biology and Oncogenic Transformation
Cote, G. J., Grubbs, E. G., & Hofmann, M.-C. C. (2015) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-22542-5_1 · Cited by 65
Mechanistic regulation of epithelial-to-mesenchymal transition through RAS signaling pathway and therapeutic implications in human cancer
Tripathi, K., & Garg, M. (2018) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-017-0441-3 · Cited by 62
CD44 targeted delivery of siRNA by using HA-decorated nanotechnologies for KRAS silencing in cancer treatment
Tirella, A., Kloc-Muniak, K., Good, L., Ridden, J., Ashford, M., Puri, S., & Tirelli, N. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.02.032 · Cited by 60
BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
Mackiewicz, J., & Mackiewicz, A. A. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.73890 · Cited by 62
The Ras–Membrane Interface: Isoform-Specific Differences in the Catalytic Domain
Parker, J. A., & Mattos, C. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0535 · Cited by 62
Strategic Combinations: The Future of Oncolytic Virotherapy with Reovirus
Zhao, X., Chester, C., Rajasekaran, N., He, Z., & Kohrt, H. E. K. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0695 · Cited by 62
Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies
Waters, A. M., Ozkan‐Dagliyan, I., Vaseva, A. V., Fer, N. D., Strathern, L. A., Hobbs, G. A., Tessier‐Cloutier, B., Gillette, W., Bagni, R., Whiteley, G., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aao3332 · Cited by 62
Self-citation
Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies
Roskoski, R. J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105579 · Cited by 62
GOLPH3 drives cell migration by promoting Golgi reorientation and directional trafficking to the leading edge
Xing, M., Peterman, M. C., Davis, R. L., Oegema, K., Shiau, A. K., & Field, S. J. (2016) · Molecular Biology of the Cell · doi:10.1091/mbc.e16-01-0005 · Cited by 60
Short-term activation of the Jun N-terminal kinase pathway in apoptosis-deficient cells of Drosophila induces tumorigenesis
Pinal, N., Martín, M. J., Medina, I., & Morata, G. (2018) · Nature Communications · doi:10.1038/s41467-018-04000-6 · Cited by 58
Cancer driver mutations in endometriosis: Variations on the major theme of fibrogenesis
Guo, S. (2018) · Reproductive Medicine and Biology · doi:10.1002/rmb2.12221 · Cited by 58
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
Ash, L. J., Busia-Bourdain, O., Okpattah, D., Kamel, A., Liberchuk, A., & Wolfe, A. L. (2024) · Current Oncology · doi:10.3390/curroncol31040150 · Cited by 68
“Sotorasib treatment not only increased the intratumoral concentration of chemokines that promote immune infiltration but also induced the expression of neoantigens on MHC class I, leading to improved antigen recognition and potentially a more robust, long-lasting antitumor T-cell response.”
Background
A Homogenous Bioluminescent System for Measuring GTPase, GTPase Activating Protein, and Guanine Nucleotide Exchange Factor Activities
Mondal, S., Hsiao, K., & Goueli, S. A. (2015) · Assay and Drug Development Technologies · doi:10.1089/adt.2015.643 · Cited by 59
Targeting the RAS/MAPK pathway withmiR-181ain acute myeloid leukemia
Huang, X., Schwind, S., Santhanam, R., Eisfeld, A., Chiang, C., Lankenau, M. A., Yu, B., Hoellerbauer, P., Jin, Y., Tarighat, S. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11150 · Cited by 59
Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation
Sheffels, E., Sealover, N. E., Wang, C., Kim, D., Vazirani, I. A., Lee, E., Terrell, E. M., Morrison, D. K., Luo, J., & Kortum, R. L. (2018) · Science Signaling · doi:10.1126/scisignal.aar8371 · Cited by 56
Quantification of spatiotemporal patterns of Ras isoform expression during development
Newlaczyl, A. U., Coulson, J. M., & Prior, I. A. (2017) · Scientific Reports · doi:10.1038/srep41297 · Cited by 59
Interaction of KRas4b with anionic membranes: A special role for PIP2
Gregory, M. C., McLean, M. A., & Sligar, S. G. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.04.063 · Cited by 58
Targeting KRAS Directly
McCormick, F. P. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-122010 · Cited by 58
Self-citation
Intrinsic protein disorder in oncogenic KRAS signaling
Nussinov, R., Jang, H., Tsai, C., Liao, T.-J., Li, S., Fushman, D., & Zhang, J. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2564-3 · Cited by 58

Authors: Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F.
Affiliations: Frederick National Laboratory for Cancer Research (US)
University of California, San Francisco (US)
Corresponding author: McCormick, Frank
ORCID: Stephen, Andrew G.
Esposito, Dominic
McCormick, Frank
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2014-03
Volume: 25
Issue: 3
Pages: 272-281
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2014.02.017
OpenAlex: W2022920832
Cited by: 795
References: 87
Citations by year: 2026: 25 · 2025: 34 · 2024: 44 · 2023: 36 · 2022: 59 · 2021: 63 · 2020: 67 · 2019: 84 · 2018: 95 · 2017: 94 · 2016: 82 · 2015: 80 · 2014: 31
FWCI: 8.85
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 404 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Funders: Frederick National Laboratory for Cancer Research
National Institutes of Health
University of California, San Francisco
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords: Ras proteins, RAS-driven cancers, undruggable proteins, Ras signaling, Ras effectors, RAS inhibitors, cancer therapy
MeSH terms: Animals, Guanosine Diphosphate, Guanosine Triphosphate, Humans, Neoplasms, Protein Processing, Post-Translational, Retroviridae Infections, Tumor Virus Infections, Signal Transduction, Oncogene Protein p21(ras), Proto-Oncogene Proteins p21(ras), Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Dragging Ras Back in the Ring

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks